Opendata, web and dolomites

I-DireCT SIGNED

Immune DIREcted and Cancer-selective immunoTherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 I-DireCT project word cloud

Explore the words cloud of the I-DireCT project. It provides you a very rough idea of what is the project "I-DireCT" about.

limits    carry    immunotherapeutics    academic    designed    ideas    immunotherapy    co    scientific    immunomodulatory    assume    restricted    young    material    chemistry    release    positions    optimal    pivotal    disciplines    uniquely    cutting    hereto    sectoral    ranging    tumor    immune    operations    academia    immunocytokines    generate    issue    breakthrough    revolutionized    network    physical    engineering    antibody    industry    inter    immunotherapeutic    formulations    innovative    stage    expertise    disciplinary    fosters    array    generation    off    bio    discoveries    training    18    expanding    months    oncology    bispecific    multidisciplinary    timed    translate    hereby    optimized    active    core    checkpoints    esr    bilateral    drug    cancer    science    combines    central    antibodies    qualified    outstanding    career    industrial    scientists    nanotech    immunology    carefully    secondments    eid    additional    doctorate    appointed    immunostimulatory    direct    sciences    biomedical    commercial    edge   

Project "I-DireCT" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS GRONINGEN 

Organization address
address: HANZEPLEIN 1
city: GRONINGEN
postcode: 9713 GZ
website: www.umcg.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙533˙358 €
 EC max contribution 2˙533˙358 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-EID
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) coordinator 929˙669.00
2    INOCURE SRO CZ (PRAHA) participant 587˙178.00
3    Surflay Nanotec GmbH DE (BERLIN) participant 505˙576.00
4    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 379˙182.00
5    KAHR MEDICAL LTD IL (JERUSALEM) participant 131˙750.00

Map

 Project objective

I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry.

Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics.

At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development.

Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "I-DIRECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "I-DIRECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More